Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study.

Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD.

Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):3071-8.

2.

Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study.

Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD.

Diabetes. 2000 Mar;49(3):485-91.

PMID:
10868972
3.

C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk.

Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD.

Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):593-8.

4.

Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects - The Hoorn Study.

Becker A, Van Hinsbergh VW, Kostense PJ, Jager A, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD.

Eur J Clin Invest. 2000 Sep;30(9):763-70.

PMID:
10998075
5.

Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study.

Jager A, Kostense PJ, Ruhé HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD.

Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):617-24.

6.

Prognostic implications of retinopathy and a high plasma von Willebrand factor concentration in type 2 diabetic subjects with microalbuminuria.

Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD.

Nephrol Dial Transplant. 2001 Mar;16(3):529-36.

7.

Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study.

Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Donker AJ, Stehouwer CD.

Arterioscler Thromb Vasc Biol. 2001 Jan;21(1):74-81.

8.

Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study.

Spijkerman AM, Dekker JM, Nijpels G, Jager A, Kostense PJ, van Hinsbergh VW, Bouter LM, Heine RJ, Stehouwer CD.

Eur J Clin Invest. 2002 Dec;32(12):924-30.

PMID:
12534452
9.

Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men.

Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Després JP, Lamarche B.

Arch Intern Med. 2001 Nov 12;161(20):2474-80.

PMID:
11700160
10.

Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study.

Cao JJ, Arnold AM, Manolio TA, Polak JF, Psaty BM, Hirsch CH, Kuller LH, Cushman M.

Circulation. 2007 Jul 3;116(1):32-8. Epub 2007 Jun 18.

11.

Why is soluble intercellular adhesion molecule-1 related to cardiovascular mortality?

Becker A, van Hinsbergh VW, Jager A, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD.

Eur J Clin Invest. 2002 Jan;32(1):1-8.

PMID:
11851720
12.

C-reactive protein and incident cardiovascular events among men with diabetes.

Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB.

Diabetes Care. 2004 Apr;27(4):889-94.

PMID:
15047644
13.

Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study.

Meigs JB, O'donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D'Agostino RB, Wilson PW.

Diabetes. 2006 Feb;55(2):530-7.

14.

Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study.

Florkowski CM, Scott RS, Coope PA, Moir CL.

Diabetes Res Clin Pract. 2001 Aug;53(2):113-20.

PMID:
11403860
15.

Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients?

Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, Li PK, Sanderson J.

J Am Soc Nephrol. 2003 Jul;14(7):1871-9.

16.

Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.

Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D, Lackner KJ, Cambien F, Blankenberg S, Tiret L; AtheroGene Investigators.

Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2793-9. Epub 2006 Oct 5.

17.

New and old cardiovascular risk factors: C-reactive protein, homocysteine, cysteine and von Willebrand factor increase risk, especially in smokers.

O'Callaghan PA, Fitzgerald A, Fogarty J, Gaffney P, Hanbidge M, Boran G, Enright H, Murphy J, McCarthy B, Graham IM.

Eur J Cardiovasc Prev Rehabil. 2005 Dec;12(6):542-7.

PMID:
16319543
18.

Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population.

Thorand B, Baumert J, Chambless L, Meisinger C, Kolb H, Döring A, Löwel H, Koenig W; MONICA/KORA Study Group.

Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):398-405. Epub 2005 Dec 1.

19.

C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly.

Strandberg TE, Tilvis RS.

Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1057-60.

20.

Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study.

Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD.

Circulation. 2000 Apr 4;101(13):1506-11.

Items per page

Supplemental Content

Write to the Help Desk